CAS: 21901-41-7; 2-Hydroxy-4-Methyl-5-Nitropyridine

相似化合物

22934-24-3 1049706-72-0 21901-34-8

上下游产品

CAS号6635-90-1 2-甲氧基-5-硝基-4-甲基吡啶 | CAS号21901-40-6 2-氨基-4-甲基-5-硝基吡啶 | CAS号695-34-1 2-氨基-4-甲基吡啶 | CAS号1049706-73-1 3-溴-2-氯-4-甲基-5-硝基吡啶 | CAS号393-53-3 3-氟吡啶-4-羧酸 | CAS号3430-27-1 3-氨基-4-甲基吡啶 | CAS号907545-47-5 2-氯-5-硝基吡啶-4-甲酸... | CAS号399-88-2 3-氟-4-甲基吡啶 | CAS号267876-19-7 1H-吡咯并[2,3-C]吡啶-5-甲胺 | CAS号5334-39-4 3-甲基-4-硝基吡唑 | CAS号6635-90-1 2-甲氧基-5-硝基-4-甲基吡啶 | CAS号1049706-72-0 3-溴-4-甲基-5-硝基-2-吡啶酮 | CAS号343-72-6 3-氟-异烟酸乙酯

2-甲氧基-4-甲基-5-硝基吡啶置于氢溴酸体系中,用 溶剂黄146 用作溶剂,化学反应 2.0H,以86%的收率获得2-羟基-4-甲基-5-硝基吡啶
参考文献:Heterocyclic Fxr Binding Compounds
标题:Heterocyclic Fxr Binding Compounds
摘要:本发明涉及与nr1H4受体(fxr)结合并作为nr1H4受体(fxr)的激动剂或部分激动剂的化合物.本发明还涉及利用这些化合物制备药物,通过这些化合物与核受体结合治疗疾病和/或病症,并涉及一种合成这些化合物的方法.

专利信息

专利号:US-7468375-B2
优先权日:2004-04-26
标题:Inhibitors of the HIV integrase enzyme
发明人：DRESS KLAUS RUPRECHT; HU QIYUE; JOHNSON TED WILLIAM; PLEWE MICHAEL BRUNO; TANIS STEVEN PAUL; WANG HAI; YANG ANLE; YIN CHUNFENG; ZHANG JUNHU
权利人:PFIZER
摘要:The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIVâ€?) integrase enzyme.

专利号:US-2009170846-A1
优先权日:2005-10-03
标题 :Inhibitors of the hiv integrase enzyme
发明人：DRESS KLAUS RUPRECHT; PLEWE MICHAEL BRUNO; JOHNSON TED WILLIAM; TANIS STEVEN PAUL; TRAN KHANH TUAN
权利人:PFIZER
摘要:The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus “HIVâ€? integrase enzyme. Formula (I).

专利号:EP-2084147-B1
优先权日:2006-08-29
标 题:Heterocyclic fxr binding compounds
发明人：KREMOSER CLAUS; DEUSCHLE ULRICH; ABEL ULRICH; SCHULZ ANDREAS
权利人:PHENEX PHARMACEUTICALS AG
摘要:The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists or partial agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.